These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35173547)

  • 1. HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer.
    Dou Z; Qiu C; Zhang X; Yao S; Zhao C; Wang Z; Chu R; Chen J; Chen Z; Li R; Wang K; Liu P; Liu C; Song K; Kong B
    Int J Biol Sci; 2022; 18(3):1188-1210. PubMed ID: 35173547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
    Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P
    ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.
    Chen D; Lin X; Gao J; Shen L; Li Z; Dong B; Zhang C; Zhang X
    Biomed Res Int; 2018; 2018():5813292. PubMed ID: 29977914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
    Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
    Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
    Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models.
    Li J; Lu J; Xu M; Yang S; Yu T; Zheng C; Huang X; Pan Y; Chen Y; Long J; Zhang C; Huang H; Dai Q; Li B; Wang W; Yao S; Pan C
    J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36378528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
    Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
    Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
    Fu J; Cai H; Wu Y; Fang S; Wang D
    Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma.
    Li L; Li X; Meng Q; Khan AQ; Chen X
    Med Sci Monit; 2018 May; 24():3050-3055. PubMed ID: 29743473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HJURP inhibits proliferation of ovarian cancer cells by regulating CENP-A/CENP-N.
    Zhang Y; Zhang W; Sun L; Yue Y; Shen D; Tian B; Du M; Dong M; Liu Y; Zhang D
    Bull Cancer; 2022 Oct; 109(10):1007-1016. PubMed ID: 35940943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
    Kim HY; Cho Y; Kang H; Yim YS; Kim SJ; Song J; Chun KH
    Oncotarget; 2016 Aug; 7(31):49902-49916. PubMed ID: 27363019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1.
    Li R; Chen J; Gao X; Jiang G
    Cancer Biol Ther; 2021 Sep; 22(7-9):465-477. PubMed ID: 34486497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
    Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
    Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine.
    Moreira DC; Venkataraman S; Subramanian A; Desisto J; Balakrishnan I; Prince E; Pierce A; Griesinger A; Green A; Eberhardt CG; Foreman NK; Vibhakar R
    J Neurooncol; 2020 May; 147(3):531-545. PubMed ID: 32180106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer.
    Liu Y; Zhu K; Guan X; Xie S; Wang Y; Tong Y; Guo L; Zheng H; Lu R
    J Ovarian Res; 2021 Oct; 14(1):128. PubMed ID: 34598710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
    Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.
    Berkel C; Cacan E
    Biochem Biophys Res Commun; 2021 Sep; 570():74-81. PubMed ID: 34273621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
    Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.